- Article
Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study
- Akinori Minato,
- Nobuki Furubayashi,
- Yujiro Nagata,
- Toshihisa Tomoda,
- Hiroyuki Masaoka,
- Yoohyun Song,
- Yoshifumi Hori,
- Keijiro Kiyoshima,
- Takahito Negishi and
- Kentaro Kuroiwa
- + 5 authors
Subtype of urothelial carcinoma (SUC), defined here as urothelial carcinoma with any histologic subtype or divergent differentiation, is a clinically aggressive disease. However, the efficacy of enfortumab vedotin (EV) against SUC remains unclear. He...